Drug Trial Radar · NCT06268886
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
310
Planned (sponsor's estimate)
Start
Mar 20, 2024
Primary completion
Dec 17, 2026
Study completion Apr 17, 2028
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Feb 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.
Conditions
- Alzheimer Disease, Early Onset
Interventions
BMS-986446Drug
Specified dose on specified days
PlaceboOther
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in brain tau deposition as measured by tau positron emission tomography (PET)Time frame: At week 76
Locations
176 sites in 10 countries. Site status is shown where the registry gives one.
Local Institution - 0068
Chandler, Arizona
Local Institution - 0102
Gilbert, Arizona
Local Institution - 0019
Phoenix, Arizona
Local Institution - 0018
Scottsdale, Arizona
Local Institution - 0026
Scottsdale, Arizona
Local Institution - 0077
Tucson, Arizona
Local Institution - 0038
Tucson, Arizona
Local Institution - 0164
Encino, California
Local Institution - 0139
Fullerton, California
Local Institution - 0191
Irvine, California
Local Institution - 0234
Long Beach, California
Local Institution - 0142
Los Alamitos, California
Local Institution - 0037
Napa, California
Local Institution - 0209
Sacramento, California
Local Institution - 0052
San Francisco, California
Local Institution - 0137
Santa Ana, California
Local Institution - 0046
Sherman Oaks, California
Local Institution - 0106
Danbury, Connecticut
Local Institution - 0148
New Haven, Connecticut
Local Institution - 0056
New Haven, Connecticut
Local Institution - 0153
Stamford, Connecticut
Local Institution - 0022
Altamonte Springs, Florida
Local Institution - 0048
Atlantis, Florida
Local Institution - 0228
Boca Raton, Florida
Local Institution - 0250
Boca Raton, Florida
Local Institution - 0224
Bradenton, Florida
Local Institution - 0020
Clermont, Florida
Local Institution - 0009
Daytona Beach, Florida
Local Institution - 0213
Fort Myers, Florida
Local Institution - 0059
Greenacres City, Florida
Local Institution - 0207
Hialeah, Florida
Local Institution - 0212
Hialeah, Florida
Local Institution - 0198
Hialeah, Florida
Local Institution - 0151
Lady Lake, Florida
Local Institution - 0146
Lakeland, Florida
Local Institution - 0192
Maitland, Florida
Local Institution - 0143
Maitland, Florida
Local Institution - 0027
Merritt Island, Florida
Local Institution - 0203
Miami, Florida
Local Institution - 0058
Miami, Florida
Showing 40 of 176 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.